ViGeneron
VeonGen Therapeutics (formerly ViGeneron) is a German clinical-stage gene therapy company developing engineered AAV-based treatments for inherited retinal diseases using three proprietary platforms (vgAAV, vgRNA REVeRT, Transactivation), and partners its vector technology with biopharma across ophthalmology and other therapeutic areas.
- Company typePrivate
- Founded2017
- HeadquartersStarnberg, Germany
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What ViGeneron does
VeonGen Therapeutics GmbH (formerly ViGeneron) is a private, clinical-stage German gene therapy company developing next-generation adeno-associated virus (AAV)-based therapeutics for ophthalmic diseases with high unmet medical need, principally inherited retinal diseases such as retinitis pigmentosa and Leber congenital amaurosis where no approved treatment currently exists. Founded in 2017 and headquartered in Planegg, Germany, the company is led by co-founder and CEO Dr. Caroline Man Xu and operates with a headcount of 11–50 employees.
The company's core asset is a stack of three proprietary AAV platforms: the vgAAV vector platform, which uses engineered AAV capsids to enable superior cell transduction and less invasive intravitreal delivery (avoiding subretinal surgery); the vgRNA REVeRT platform, which circumvents the ~5Kb AAV packaging ceiling by splitting large genes across multiple vectors and reconstituting full-length protein through mRNA trans-splicing; and the Transactivation platform, which enables simultaneous modulation of multiple genes (amplification plus knockout) independent of gene size. These platforms support two in-house lead ophthalmic programs and are designed to be deployed across additional tissues including CNS, heart, pancreas, and skeletal muscle.
VeonGen's commercial model is partnership-led rather than product-led. As a pre-revenue biotech, the firm self-funds an ophthalmic pipeline while seeking co-development and licensing agreements with biopharmaceutical partners to apply its platforms to neuroscience, diabetes, cardiovascular, and muscular disease indications. Revenue, when it materializes, is expected to flow from upfront payments, milestone payments, development funding, and royalties on partnered programs.
ViGeneron firmographics
Firmographics- Name
- ViGeneron
- Legal name
- VeonGen Therapeutics GmbH
- Website
- https://vigeneron.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- VeonGen Therapeutics (formerly ViGeneron) is a German clinical-stage gene therapy company developing engineered AAV-based treatments for inherited retinal diseases using three proprietary platforms (vgAAV, vgRNA REVeRT, Transactivation), and partners its vector technology with biopharma across ophthalmology and other therapeutic areas.
- Ownership category
- akta.pro rank
ViGeneron industry classification
Industry- Product category
- Ophthalmic Gene Therapy
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Ophthalmology Gene Therapies (HLAAACAG)
- akta.pro secondary industries
- AAV Vector Gene Therapy Developers (HLAAACAA), Neurology/CNS Gene Therapies (HLAAACAH), Cardiometabolic & Other Systemic Gene Therapies (HLAAACAI)
Keywords
Where ViGeneron is headquartered
LocationHeadquarters
- HQ city
- Starnberg
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
ViGeneron business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Gene Therapy Development and Licensing: Pre-revenue biotech company developing novel gene therapy platforms and pipeline candidates for inherited retinal diseases. Revenue generation model expected through licensing deals, partnerships, and eventual product commercialization pending clinical success and regulatory approvals.
Go-to-market motion1 record
Marketing channels1 record
ViGeneron product offering
Product offeringCore offering
ViGeneron (now VeonGen Therapeutics) develops next-generation adeno-associated virus (AAV)-based gene therapy platforms (vgAAV, vgRNA REVeRT, and Transactivation) to address limitations of existing AAV therapies. The company uses these platforms to build an internal pipeline of ophthalmic gene therapies, with two lead programs targeting inherited retinal diseases where no approved treatment options exist, while also leveraging the platforms through partnerships with biopharmaceutical players in neuroscience, diabetes, cardiovascular, and muscular disease areas.
Product overview
ViGeneron (now VeonGen Therapeutics) is a next generation gene therapy company developing three proprietary technology platforms: vgAAV (novel engineered AAV capsids), vgRNA REVeRT (overcoming gene size limitations via mRNA trans-splicing), and Transactivation (multi-gene modulation via CRISPR). The company leverages these platforms to build an internal pipeline in ophthalmic gene therapy for inherited retinal diseases, with two lead programs in development for conditions with no approved treatment options currently available.
Differentiator
Problem solved
Functional benefit
Products and services
- vgAAV Vector Platform
Quantifiable outcome
- Enables delivery of genes larger than 5Kb, overcoming traditional AAV packaging limitations
- +1 more outcomes
Companies that use ViGeneron
Customer profileSegments1 record
Ideal customer profiles2 records
ViGeneron technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
ViGeneron partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Biopharmaceutical Partners (unspecified)coreVeonGen seeks to leverage its next generation vector platforms in partnerships with biopharmaceutical players in disease areas beyond ophthalmology, including neuroscience, diabetes, cardiovascular, and muscular diseases. The company also explores opportunities with leading biopharmaceutical partners based on their novel gene therapy techniques developed from well-founded scientific results.
Scale indicators2 records
Recent moves6 records
Expansion highlights5 records
ViGeneron competitors and assessment
Company assessmentDirect peers
- 4D Molecular Therapeutics: Clinical-stage AAV gene therapy company developing engineered capsids for ophthalmology, cardiology, pulmonology, and CNS. Direct competitor with comparable platform-plus-pipeline strategy and emphasis on novel capsid design.
- Adverum Biotechnologies: AAV-based gene therapy developer focused on ocular diseases (wet AMD, diabetic macular edema) and rare diseases. Directly comparable as an ophthalmology-anchored AAV platform pursuing intravitreal delivery and partnered development model.
- REGENXBIO: Pioneer in AAV gene therapy delivery with proprietary NAV technology platform; actively developing and partnering AAV treatments for retinal, CNS, and metabolic indications. Highly comparable as a platform-driven AAV licensing and product company.
- Generation Bio: Non-viral gene therapy company addressing the size and re-dosing limitations of AAV, including ophthalmology and liver indications. Directly comparable as a company building an alternative delivery platform to overcome AAV constraints.
- MeiraGTx Holdings: Clinical-stage gene therapy company developing treatments for inherited retinal diseases, CNS disorders, and other serious conditions. Comparable because of its ophthalmic lead programs (RP, LCA) that directly overlap VeonGen's target indications.
- Abeona Therapeutics: Clinical-stage gene therapy company with ophthalmology and rare disease programs using AAV. Comparable as a small-cap, multi-platform AAV developer pursuing inherited retinal disease treatments.
- GenSight Biologics: Clinical-stage gene therapy company developing AAV-based treatments for inherited retinal diseases including Leber Hereditary Optic Neuropathy. Comparable in scale, stage, and ophthalmic gene therapy focus.
Broad incumbents
- Spark Therapeutics (Roche): Acquired by Roche; developed and commercialized Luxturna, the first FDA-approved AAV gene therapy for an inherited retinal disease. Sets the regulatory and commercial benchmark against which ophthalmic AAV developers like VeonGen are evaluated.
- BioMarin Pharmaceutical: Commercial-stage biotech that markets Roctavian (hemophilia A) and previously controlled Luxturna outside the US. A broader gene therapy incumbent with deep regulatory, CMC, and commercial infrastructure relevant to VeonGen's ophthalmology ambitions.
Emerging players
- Coave Therapeutics: European clinical-stage gene therapy company developing AAV-based therapies for CNS and ophthalmic rare diseases; structurally similar in size and stage to VeonGen with comparable platform-licensing business model.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
ViGeneron social profiles
Digital presenceViGeneron financial estimates
Financial estimateRevenue estimate
Valuation estimate
ViGeneron leadership team
Management profileNumber of profiles
Profiles1 record
ViGeneron funding detail
Funding detailFunding overview
Funding rounds2 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ViGeneron M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ViGeneron
What does ViGeneron do?
ViGeneron (now VeonGen Therapeutics) develops next-generation adeno-associated virus (AAV)-based gene therapy platforms (vgAAV, vgRNA REVeRT, and Transactivation) to address limitations of existing AAV therapies. The company uses these platforms to build an internal pipeline of ophthalmic gene therapies, with two lead programs targeting inherited retinal diseases where no approved treatment options exist, while also leveraging the platforms through partnerships with biopharmaceutical players in neuroscience, diabetes, cardiovascular, and muscular disease areas.
Is ViGeneron a public or private company?
ViGeneron is a private company. It is classified as venture growth investor backed and is currently operating.
When was ViGeneron founded?
ViGeneron was founded in 2017. It employs 11 to 50 people.
Where is ViGeneron based?
ViGeneron is headquartered in Starnberg, Germany, in the Europe region.
How does ViGeneron make money?
One revenue line is on record: gene Therapy Development and Licensing.
Who are ViGeneron's main competitors?
Direct peers on record are 4D Molecular Therapeutics, Adverum Biotechnologies, REGENXBIO, Generation Bio, MeiraGTx Holdings, Abeona Therapeutics and GenSight Biologics. Broad incumbents are Spark Therapeutics (Roche) and BioMarin Pharmaceutical. Coave Therapeutics is listed as an emerging player.
Does ViGeneron have an API?
No public API is recorded for ViGeneron.
What industry is ViGeneron in?
ViGeneron's product category is Ophthalmic Gene Therapy. Its primary akta.pro industry code is HLAAACAG, Ophthalmology Gene Therapies, with a secondary code of HLAAACAA, AAV Vector Gene Therapy Developers. Its NAICS code is 541714 and its SIC code is 2836.